These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 7500787)

  • 1. ACE inhibitors and diabetics with albuminuria. The DIABHYCAR Study Group.
    Marre M; Lievre M; Chatellier G; Plouin PF
    Lancet; 1995 Dec; 346(8990):1638. PubMed ID: 7500787
    [No Abstract]   [Full Text] [Related]  

  • 2. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microalbuminuria and ACE inhibition in non-hypertensive diabetics.
    Marre M
    J Diabet Complications; 1990; 4(2):84-5. PubMed ID: 2145309
    [No Abstract]   [Full Text] [Related]  

  • 4. Over 11 years of stable renal function after remission of nephrotic-range proteinuria in type I diabetics treated with an ACE inhibitor.
    McGregor D; Bailey RR
    Nephron; 1997; 76(3):270-5. PubMed ID: 9226226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of ACE inhibition on the course of nephropathy in type I diabetes mellitus.
    Meinders AE; Hes R; de Leeuw PW
    Neth J Med; 1992 Jun; 40(5-6):217-20. PubMed ID: 1436257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy.
    Bakris GL
    Ann Intern Med; 1993 Apr; 118(8):643-4. PubMed ID: 8452332
    [No Abstract]   [Full Text] [Related]  

  • 7. ACE inhibitor intervention in Type 1 diabetes with low grade microalbuminuria.
    Poulsen PL
    J Renin Angiotensin Aldosterone Syst; 2003 Mar; 4(1):17-26. PubMed ID: 12692749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].
    Shionoiri H; Yasuda G; Takizawa T; Shionoiri F
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():394-9. PubMed ID: 15999741
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
    Bakris GL; Toto RD; McCullough PA; Rocha R; Purkayastha D; Davis P;
    Kidney Int; 2008 Jun; 73(11):1303-9. PubMed ID: 18354383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personal viewpoint: new developments in the therapy of diabetic hypertensive disease. The ABCD study adds to strong evidence favoring the prime use of ACE inhibitors. Appropriate Blood Pressure Control in Diabetes.
    Opie LH
    Cardiovasc Drugs Ther; 1998 Jul; 12(3):233-8. PubMed ID: 9784901
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy.
    Imanishi M; Yoshioka K; Okumura M; Konishi Y; Tanaka S; Fujii S; Kimura G
    Kidney Int Suppl; 1997 Dec; 63():S198-200. PubMed ID: 9407458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [ACE inhibitors and early diabetic nephropathy].
    Bangstad HJ; Hartmann A; Berg TJ; Hanssen KF
    Tidsskr Nor Laegeforen; 1995 Oct; 115(24):3039-41. PubMed ID: 7570536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should Angiotensin converting enzyme inhibitors be used in children with type 1 diabetes and microalbuminuria?
    Almerie MQ; Williams RM; Acerini CL
    Arch Dis Child; 2008 Jul; 93(7):633-5. PubMed ID: 18285389
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A; Tabata M; Hayashi K; Saruta T
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACE inhibitors and hypoglycaemia.
    van Haeften TW
    Lancet; 1995 Jul; 346(8967):125; author reply 126-7. PubMed ID: 7603198
    [No Abstract]   [Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors.
    Mazerska M; Myśliwiec M
    Adv Med Sci; 2009; 54(1):37-40. PubMed ID: 19505872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Who is tested for diabetic kidney disease and who initiates treatment? The Translating Research Into Action For Diabetes (TRIAD) Study.
    Johnson SL; Tierney EF; Onyemere KU; Tseng CW; Safford MM; Karter AJ; Ferrara A; Duru OK; Brown AF; Narayan KM; Thompson TJ; Herman WH
    Diabetes Care; 2006 Aug; 29(8):1733-8. PubMed ID: 16873772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
    Jacobsen P; Andersen S; Rossing K; Jensen BR; Parving HH
    Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.